Latest From Daniel Chancellor
Portfolio decisions for pharma pipelines are multifactorial, although patient need perhaps does not get the attention it merits. Rather, the gravitational pull around risk, investment return, and regulatory incentive tilts the pharma pipeline toward overconcentration in hot therapy areas.
With a declining share of global R&D and investment, Europe risks the pharmaceutical industry being increasingly molded in the image of others.
Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.
This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.
Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.
As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects COVID-19 has brought. For the biopharmaceutical industry, clinical trials have been at the forefront.